Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABRE: BMS-986414 and BMS-986413 in Vaccine Non-responders
NCT05393999Phase 2Withdrawn
- Sponsor
- Imperial College Healthcare NHS Trust
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BMS-986414 and crexavibart in coronavirus disease 2019 (COVID-19), sponsored by Imperial College Healthcare NHS Trust. Primary endpoints: Adverse Event of Interest at 12 weeks, Serious Adverse Event at 12 weeks and 2 more. Planned start Nov 2021; status: withdrawn.
02
Drugs
BMS-986414crexavibart
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05393999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393999.